Hepatitis B Clinical Trials 2024

What are the top hospitals conducting hepatitis b research?

In the ongoing fight against hepatitis b, several top hospitals are at the forefront of groundbreaking clinical trials. One such institution is the University of California, San Francisco (UCSF) located in vibrant San Francisco. UCSF currently has three active trials dedicated to hepatitis B, with a cumulative total of seven trials conducted over time. Their pioneering efforts began back in 1999 when they recorded their first trial for this condition.

Moving eastward to Aurora, Colorado, we find the University of Colorado Hospital CRS making significant contributions to hepatitis B research. With two active trials and a small but impactful history of three previous studies on this disease, this hospital continues to push boundaries since embarking on their first hepatitis B trial just last year in 2020.

Meanwhile, across the country in Washington D.C., Whitman-Walker Health CRS is also actively involved in fighting against hepatitis B with two ongoing clinical trials. Their commitment began recently as well when they initiated their first recorded trial for this condition alongside The Ponce de Leon Center CRS based in Atlanta and Northwestern University CRS located within Chicago both showcasing similar dedication by conducting hepatisisb related research through two active projects while having participation experience before once again since entering into field coincidingly only from 2020 onwards.

These hospitals play vital roles not only by offering hope to those affected by hepatitis B but also by pushing forward our understanding and treatment options for this serious liver infection that affects millions worldwide. Through these clinical trials conducted across various locations throughout the United States - from sunny San Francisco all the way to bustling Chicago - medical professionals are working diligently towards finding new treatments and ultimately striving for better outcomes for patients living with hepatitis B

Which are the best cities for hepatitis b clinical trials?

When it comes to hepatitis b clinical trials, several cities stand out as hubs for cutting-edge research. In New york, there are currently 17 active trials exploring treatments like Selgantolimod and HEPLISAV-B among others. San Francisco follows closely behind with 12 ongoing studies that investigate interventions such as stopping NA therapy and utilizing Selgantolimod. Honolulu in Hawaii also boasts 12 active trials focusing on Tenofovir Alafenamide and other potential breakthroughs. Lastly, Los Angeles and Houston both contribute to the advancement of hepatitis B research with their respective nine and eight active trials studying various treatment options. Through these dedicated efforts in multiple cities across the United States, researchers strive to improve outcomes for individuals affected by hepatitis B infection.

Which are the top treatments for hepatitis b being explored in clinical trials?

Exciting advancements are underway in the clinical trials exploring treatments for hepatitis b. Among the top contenders is GSK3228836, currently being tested in two active trials and with a total of six all-time hepatitis B trials since its introduction in 2020. Another promising option is JNJ-73763989, which has also gained traction with two ongoing trials and nine all-time hepatitis B studies since it was first listed in 2019. Additionally, Tenofovir Alafenamide shows promise as a treatment option with two active trials and an impressive tally of 18 all-time hepatitis B trials dating back to 2010. Lastly, keep an eye on bepirovirsen, a newcomer to the scene that has already initiated two active clinical trials after its listing in 2022. As research progresses further into these various investigational treatments, hope continues to grow for patients affected by hepatitis B worldwide.

What are the most recent clinical trials for hepatitis b?

Exciting developments in the field of hepatitis b research have brought forth promising clinical trials that may pave the way for improved treatment options. One such trial is Active, a Phase 2 study that aims to assess the efficacy and safety of a new intervention for hepatitis B. Additionally, Group 1a investigates the potential benefits of HepB mAb19 administered intravenously, with Phase 1 focusing on determining its safety profile. Another noteworthy trial is Selgantolimod, currently in Phase 2, which holds promise as a potential therapeutic agent against hepatitis B. The development and evaluation of these innovative treatments signify significant progress towards addressing this challenging condition and improving patient outcomes.

What hepatitis b clinical trials were recently completed?

Recently, several important clinical trials investigating potential treatments for hepatitis b have reached completion. In September 2021, GlaxoSmithKline concluded a trial studying the effectiveness of GSK3228836. Additionally, Nucorion Pharmaceuticals wrapped up their investigation into NCO-48 Fumarate 20 mg in January 2021. Another trial involving GSK3228836 by GlaxoSmithKline was completed in July 2020. Furthermore, Janssen Sciences Ireland UC completed their study on JNJ-73763989 back in August 2019. Finally, the University of Maryland conducted a trial exploring the benefits of B/F/TAF that finished in April 2019. These recent advancements mark significant progress towards improving treatments for hepatitis B and offer hope to those affected by this persistent virus.